Drug Trial Radar · NCT05581303
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
7,297
Actual
Start
Dec 14, 2022
Primary completion
Mar 31, 2028
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Oct 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this trial is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).
Conditions
- Atherosclerotic Cardiovascular Disease
Interventions
PlaceboDrug
Placebo given by subcutaneous injection once every 12 weeks (Q12W).
OlpasiranDrug
Olpasiran given by subcutaneous injection Q12W.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to CHD death, myocardial infarction, or urgent coronary revascularization, whichever occurs firstTime frame: Approximately 5 years
Locations
492 sites in 24 countries. Site status is shown where the registry gives one.
University of Alabama Saint Vincent's Birmingham
Birmingham, Alabama
Grandview Medical Center Affinity Cardiovascular Specialists, LLC
Birmingham, Alabama
Huntsville Clinical Research, LLC
Huntsville, Alabama
Mobile Heart Specialists PC
Mobile, Alabama
HonorHealth Research and Innovation Institute
Phoenix, Arizona
Elite Clinical Studies LLC
Phoenix, Arizona
National Heart Institute
Beverly Hills, California
Pacific Oaks Medical Group
Beverly Hills, California
University of California San Diego
La Jolla, California
VA Greater Los Angeles Healthcare System
Los Angeles, California
University of California Irvine
Orange, California
University of California Los Angeles
Santa Monica, California
Manshadi Heart Institute
Stockton, California
Med Partners, Inc dba Premiere Medical Center, Inc
Toluca Lake, California
UCHealth Memorial Central
Colorado Springs, Colorado
Cardiology Associates of Fairfield County PC
Stamford, Connecticut
MedStar Clinical Research
Washington D.C., District of Columbia
Bay Area Cardiology
Brandon, Florida
Clearwater Cardiovascular Consultants
Clearwater, Florida
Cardiology Associates Research LLC
Daytona Beach, Florida
Jellinger and Lerman MD PA dba The Center for Diabetes and Endocrine Care
Fort Lauderdale, Florida
Elite Cardiac Research Center LLC
Hialeah, Florida
East Coast Institute for Research, LLC
Jacksonville, Florida
Westside Center for Clinical Research
Jacksonville, Florida
University of Florida
Jacksonville, Florida
East Coast Institute for Research LLC
Jacksonville, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Excel Medical Clinical Trials
Miami, Florida
Advanced Research for Health Improvement, LLC
Naples, Florida
Ocala Cardiovascular Research
Ocala, Florida
AdventHealth Medical Group Cardiology at Orlando
Orlando, Florida
East Coast Institute for Research, LLC
Saint Augustine, Florida
Saint Johns Center for Clinical Research
Saint Augustine, Florida
Cardiovascular Center of Sarasota
Sarasota, Florida
Piedmont Healthcare
Atlanta, Georgia
Morehouse School of Medicine
Atlanta, Georgia
Northeast Georgia Medical Center Wisteria Building
Cumming, Georgia
Nsc Research
Johns Creek, Georgia
St Lukes Idaho
Meridian, Idaho
Endeavor Health-Northwest Community Healthcare
Arlington Heights, Illinois
Showing 40 of 492 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.